Evidence map›Paper›PMID 35669785›Full record

ArticleFrontiers in immunology2022

Immunization with CSP and a RIG-I Agonist is Effective in Inducing a Functional and Protective Humoral Response Against

Ana Rafaela Teixeira, Begoña Pérez-Cabezas, David M Costa, Mónica Sá, Sylvain Golba, Hélèna Sefiane-Djemaoune, Joana Ribeiro, Izumi Kaneko, Shiroh Iwanaga, Masao Yuda and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

Ana Rafaela TeixeiraHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Begoña Pérez-CabezasHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
David M CostaHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Mónica SáHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Sylvain GolbaCenter for Production and Infection of Anopheles, Institut Pasteur, Paris, France.
Hélèna Sefiane-DjemaouneCenter for Production and Infection of Anopheles, Institut Pasteur, Paris, France.
Joana RibeiroHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Izumi KanekoDepartment of Medical Zoology, Mie University Graduate School of Medicine, Mie, Japan.
Shiroh IwanagaResearch Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Masao YudaDepartment of Medical Zoology, Mie University Graduate School of Medicine, Mie, Japan.
Moriya TsujiAaron Diamond AIDS Research Center, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Silvia Beatriz BoscardinInstitute for Investigation in Immunology (iii)-INCT, São Paulo, Brazil.
Rogerio AminoUnit of Malaria Infection and Immunity, Institut Pasteur, Paris, France.
Anabela Cordeiro-da-SilvaInstituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.
Joana TavaresHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTInstitut Pasteur · FRMie University · JPUniversidade do Porto · PTAaron Diamond AIDS Research Center · USOsaka University · JPUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria is a major public health concern, as a highly effective human vaccine remains elusive. The efficacy of a subunit vaccine targeting the most abundant protein of the sporozoite surface, the circumsporozoite protein (CSP) has been hindered by difficulties in generating an effective humoral response in both quantity and quality. Using the rodent

Indexed as

Malaria VaccinesAdjuvants, ImmunologicAnimalsAntibodies, ProtozoanImmunizationMicePlasmodium falciparumProtozoan ProteinsSporozoitesAdjuvants, ImmunologicAntibodies, ProtozoanMalaria VaccinesProtozoan ProteinsadjuvantsCSPmalariaPlasmodiumRLR agonistssporozoitessubunit vaccinesTLR3 agonist

Identifiers

PMID35669785
PMCPMC9163323
OpenAlexW4280520383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.